Brief: CytoDyn Receives Clearance from Brazil’s FDA (ANVISA) to start Pivotal Trial in COVID-19 Patients

Cytodyn

22/09/2021 13:17

Sept 22 (Reuters) - Cytodyn Inc  CYDY.PK :
    * CYTODYN RECEIVES CLEARANCE FROM BRAZIL’S FDA (ANVISA) TO
COMMENCE A PIVOTAL PHASE 3 TRIAL IN CRITICALLY ILL COVID-19
PATIENTS WITH IV ADMINISTRATION OF FOUR DOSES (700MG/WEEK)

Source text for Eikon:  ID:nBw6FkGJma 
Further company coverage:  CYDY.PK 

 ((Reuters.Briefs@thomsonreuters.com;))